8-K
JOHNSON & JOHNSON (JNJ)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
July 24, 2023
Johnson & Johnson
(Exact name of registrant as specified in its charter)
| New Jersey | 1-3215 | 22-1024240 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange |
| 0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange |
| 5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange |
| 1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange |
| 1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange |
Item 8.01 Other Events
The information contained in Exhibit 99.1 is hereby incorporated by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Certainpreliminaryresults for the period ended July 2, 2023 |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Johnson & Johnson | |||
|---|---|---|---|
| (Registrant) | |||
| Date: | July 24, 2023 | By: | /s/ Robert J. Decker, Jr. |
| Robert J. Decker, Jr.<br>Controller<br>(Principal Accounting Officer) |
Document
Exhibit 99.1
The following are certain preliminary results of selected unaudited financial and other information of Johnson & Johnson for the fiscal three and six months ended July 2, 2023 and actual unaudited financial results of Johnson & Johnson for the three and six months ended July 3, 2022. Johnson & Johnson has provided certain preliminary results below; however, its closing procedures for the fiscal three and six months ended July 2, 2023 are not yet complete. Johnson & Johnson’s actual results for the fiscal three and six months ended July 2, 2023 remain subject to the completion of management’s final review and Johnson & Johnson’s other closing procedures, or subsequent events, as well as the completion of the review of Johnson & Johnson’s financial statements. Accordingly, you should not place undue reliance on these preliminary results set out below, which may differ from actual results. During the course of the preparation of Johnson & Johnson’s unaudited consolidated financial statements and the notes thereto, additional items that require adjustments to the preliminary results presented below may be identified.
The preliminary financial data of Johnson & Johnson included below has been prepared by, and is the responsibility of, Johnson & Johnson’s management. Johnson & Johnson's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.
The preliminary and actual results of Johnson & Johnson provided below do not represent a comprehensive statement of Johnson & Johnson’s financial results and should not be viewed as a substitute for unaudited consolidated financial results prepared in accordance with GAAP. In addition, the preliminary results for the fiscal three and six months ended July 2, 2023 are not necessarily indicative of the results to be achieved in any future period.
OVERALL FINANCIAL RESULTS:
| Q2 | |||
|---|---|---|---|
| ($ in Millions, except EPS) | 2023 (Preliminary) | 2022 (Actual) | % Change |
| Reported Sales | $25,530 | $24,020 | 6.3% |
| Net Earnings/(Loss) | $5,144 | $4,814 | 6.9% |
| EPS (diluted) | $1.96 | $1.80 | 8.9% |
REGIONAL SALES RESULTS:
| Q2 | % Change | ||
|---|---|---|---|
| ($ in Millions) | 2023 (Preliminary) | 2022 (Actual) | Reported |
| U.S. | $13,444 | $12,197 | 10.2% |
| International | 12,086 | 11,823 | 2.2 |
| Worldwide | $25,530 | $24,020 | 6.3% |
Note: values may have been rounded
SEGMENT SALES RESULTS:
| Q2 | % Change | ||
|---|---|---|---|
| ($ in Millions) | 2023 (Preliminary) | 2022 (Actual) | Reported |
| Consumer Health | $4,011 | $3,805 | 5.4% |
| Pharmaceutical | 13,731 | 13,317 | 3.1 |
| MedTech | 7,788 | 6,898 | 12.9 |
| Worldwide | $25,530 | $24,020 | 6.3% |
Note: Values may have been rounded
| Johnson & Johnson and Subsidiaries | |||||||
|---|---|---|---|---|---|---|---|
| Supplementary Sales Data | (Unaudited; Dollars in Millions) | SECOND QUARTER | |||||
| --- | --- | --- | --- | --- | --- | ||
| Percent Change | |||||||
| 2023 (Preliminary) | 2022 (Actual) | Total | |||||
| Sales to customers by | |||||||
| geographic area | |||||||
| U.S. | $ | 13,444 | 12,197 | 10.2 | % | ||
| Europe | 5,894 | 6,085 | (3.1) | ||||
| Western Hemisphere excluding U.S. | 1,713 | 1,536 | 11.5 | ||||
| Asia-Pacific, Africa | 4,479 | 4,202 | 6.6 | ||||
| International | 12,086 | 11,823 | 2.2 | ||||
| Worldwide | $ | 25,530 | 24,020 | 6.3 | % |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
| Johnson & Johnson and Subsidiaries | |||||||
|---|---|---|---|---|---|---|---|
| Supplementary Sales Data | (Unaudited; Dollars in Millions) | SIX MONTHS | |||||
| --- | --- | --- | --- | --- | --- | ||
| Percent Change | |||||||
| 2023 (Preliminary) | 2022 (Actual) | Total | |||||
| Sales to customers by | |||||||
| geographic area | |||||||
| U.S. | $ | 25,961 | 23,611 | 10.0 | % | ||
| Europe | 12,226 | 12,109 | 1.0 | ||||
| Western Hemisphere excluding U.S. | 3,300 | 3,018 | 9.3 | ||||
| Asia-Pacific, Africa | 8,789 | 8,708 | 0.9 | ||||
| International | 24,315 | 23,835 | 2.0 | ||||
| Worldwide | $ | 50,276 | 47,446 | 6.0 | % |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
| Johnson & Johnson and Subsidiaries | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supplementary Sales Data | (Unaudited; Dollars in Millions) | SECOND QUARTER | SIX MONTHS | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| Percent <br>Change | Percent Change | |||||||||||
| 2023 (Preliminary) | 2022 (Actual) | Total | 2023 (Preliminary) | 2022 (Actual) | Total | |||||||
| Sales to customers by | ||||||||||||
| segment of business | ||||||||||||
| Consumer Health | ||||||||||||
| U.S. | $ | 1,787 | 1,687 | 6.0 | % | $ | 3,522 | 3,244 | 8.6 | % | ||
| International | 2,224 | 2,118 | 5.0 | 4,341 | 4,147 | 4.7 | ||||||
| 4,011 | 3,805 | 5.4 | 7,863 | 7,391 | 6.4 | |||||||
| Pharmaceutical (1) | ||||||||||||
| U.S. | 7,818 | 7,159 | 9.2 | 14,841 | 13,791 | 7.6 | ||||||
| International | 5,913 | 6,158 | (4.0) | 12,303 | 12,395 | (0.7) | ||||||
| 13,731 | 13,317 | 3.1 | 27,144 | 26,186 | 3.7 | |||||||
| Pharmaceutical excluding COVID-19 Vaccine (1) | ||||||||||||
| U.S. | 7,818 | 7,114 | 9.9 | 14,841 | 13,671 | 8.6 | ||||||
| International | 5,628 | 5,659 | (0.5) | 11,271 | 11,514 | (2.1) | ||||||
| 13,446 | 12,773 | 5.3 | 26,112 | 25,185 | 3.7 | |||||||
| MedTech | ||||||||||||
| U.S. | 3,839 | 3,351 | 14.6 | 7,598 | 6,576 | 15.5 | ||||||
| International | 3,949 | 3,547 | 11.3 | 7,671 | 7,293 | 5.2 | ||||||
| 7,788 | 6,898 | 12.9 | 15,269 | 13,869 | 10.1 | |||||||
| U.S. | 13,444 | 12,197 | 10.2 | 25,961 | 23,611 | 10.0 | ||||||
| International | 12,086 | 11,823 | 2.2 | 24,315 | 23,835 | 2.0 | ||||||
| Worldwide | 25,530 | 24,020 | 6.3 | 50,276 | 47,446 | 6.0 | ||||||
| U.S. | 13,444 | 12,152 | 10.6 | 25,961 | 23,491 | 10.5 | ||||||
| International | 11,801 | 11,324 | 4.2 | 23,283 | 22,954 | 1.4 | ||||||
| Worldwide excluding COVID-19 Vaccine (1) | $ | 25,245 | 23,476 | 7.5 | % | $ | 49,244 | 46,445 | 6.0 | % |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1)Refer to supplemental sales reconciliation schedules.
| Johnson & Johnson and Subsidiaries | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Condensed Consolidated Statement of Earnings | (Unaudited; in Millions Except Per Share Figures) | SECOND QUARTER | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 2023 (Preliminary) | 2022 (Actual) | Percent<br>Increase<br>(Decrease) | |||||||||
| Amount | Percent<br><br>to Sales | Amount | Percent<br><br>to Sales | ||||||||
| Sales to customers | $ | 25,530 | 100.0 | $ | 24,020 | 100.0 | 6.3 | ||||
| Cost of products sold | 8,212 | 32.2 | 7,919 | 33.0 | 3.7 | ||||||
| Gross Profit | 17,318 | 67.8 | 16,101 | 67.0 | 7.6 | ||||||
| Selling, marketing and administrative expenses | 6,665 | 26.1 | 6,226 | 25.9 | 7.1 | ||||||
| Research and development expense | 3,829 | 15.0 | 3,703 | 15.4 | 3.4 | ||||||
| Interest (income) expense, net | (23) | (0.1) | (26) | (0.1) | |||||||
| Other (income) expense, net* | (60) | (0.2) | 273 | 1.1 | |||||||
| Restructuring | 145 | 0.5 | 85 | 0.4 | |||||||
| Earnings before provision for taxes on income | 6,762 | 26.5 | 5,840 | 24.3 | 15.8 | ||||||
| Provision for taxes on income | 1,618 | 6.4 | 1,026 | 4.3 | 57.7 | ||||||
| Net earnings | $ | 5,144 | 20.1 | $ | 4,814 | 20.0 | 6.9 | ||||
| Net earnings per share (Diluted) | $ | 1.96 | $ | 1.80 | 8.9 | ||||||
| Average shares outstanding (Diluted) | 2,625.7 | 2,667.9 | |||||||||
| Effective tax rate | 23.9 | % | 17.6 | % |
* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
| Johnson & Johnson and Subsidiaries | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Condensed Consolidated Statement of Earnings | (Unaudited; in Millions Except Per Share Figures) | SIX MONTHS | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 2023 (Preliminary) | 2022 (Actual) | Percent<br>Increase<br>(Decrease) | |||||||||
| Amount | Percent<br>to Sales | Amount | Percent<br>to Sales | ||||||||
| Sales to customers | $ | 50,276 | 100.0 | $ | 47,446 | 100.0 | 6.0 | ||||
| Cost of products sold | 16,607 | 33.0 | 15,517 | 32.7 | 7.0 | ||||||
| Gross Profit | 33,669 | 67.0 | 31,929 | 67.3 | 5.4 | ||||||
| Selling, marketing and administrative expenses | 12,803 | 25.5 | 12,164 | 25.6 | 5.3 | ||||||
| Research and development expense | 7,392 | 14.7 | 7,165 | 15.1 | 3.2 | ||||||
| In-process research and development | 49 | 0.1 | 610 | 1.3 | |||||||
| Interest (income) expense, net | (43) | (0.1) | (38) | (0.1) | |||||||
| Other (income) expense, net* | 7,168 | 14.3 | 171 | 0.4 | |||||||
| Restructuring | 275 | 0.5 | 155 | 0.3 | |||||||
| Earnings before provision for taxes on income | 6,025 | 12.0 | 11,702 | 24.7 | (48.5) | ||||||
| Provision for taxes on income | 949 | 1.9 | 1,739 | 3.7 | (45.4) | ||||||
| Net earnings | $ | 5,076 | 10.1 | $ | 9,963 | 21.0 | (49.1) | ||||
| Net earnings per share (Diluted) | $ | 1.93 | $ | 3.73 | (48.3) | ||||||
| Average shares outstanding (Diluted) | 2,630.7 | 2,669.2 | |||||||||
| Effective tax rate | 15.8 | % | 14.9 | % |
* Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| SECOND QUARTER | SIX MONTHS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| % Change | % Change | |||||||||
| 2023 (Preliminary) | 2022 (Actual) | Reported | 2023 (Preliminary) | 2022 (Actual) | Reported | |||||
| CONSUMER HEALTH SEGMENT (1) | ||||||||||
| OTC | ||||||||||
| US | $ | 712 | 663 | 7.5 | % | $ | 1,457 | 1,333 | 9.3 | % |
| Intl | 947 | 818 | 15.7 | 1,844 | 1,609 | 14.6 | ||||
| WW | 1,659 | 1,482 | 12.0 | 3,301 | 2,943 | 12.2 | ||||
| SKIN HEALTH / BEAUTY | ||||||||||
| US | 650 | 629 | 3.4 | 1,267 | 1,173 | 8.0 | ||||
| Intl | 498 | 497 | 0.3 | 991 | 965 | 2.7 | ||||
| WW | 1,148 | 1,126 | 2.0 | 2,258 | 2,138 | 5.6 | ||||
| ORAL CARE | ||||||||||
| US | 173 | 170 | 1.7 | 332 | 313 | 6.2 | ||||
| Intl | 225 | 224 | 0.3 | 427 | 447 | (4.7) | ||||
| WW | 398 | 394 | 0.9 | 759 | 760 | (0.2) | ||||
| BABY CARE | ||||||||||
| US | 99 | 88 | 12.5 | 195 | 173 | 12.7 | ||||
| Intl | 261 | 287 | (9.1) | 524 | 557 | (6.0) | ||||
| WW | 360 | 375 | (4.0) | 719 | 730 | (1.6) | ||||
| WOMEN'S HEALTH | ||||||||||
| US | 4 | 3 | (2.1) | 7 | 7 | (0.1) | ||||
| Intl | 235 | 228 | 3.5 | 449 | 452 | (0.7) | ||||
| WW | 238 | 230 | 3.4 | 455 | 458 | (0.6) | ||||
| WOUND CARE / OTHER | ||||||||||
| US | 149 | 133 | 12.3 | 264 | 245 | 7.9 | ||||
| Intl | 58 | 65 | (10.3) | 107 | 117 | (8.4) | ||||
| WW | 207 | 197 | 4.9 | 371 | 361 | 2.6 | ||||
| TOTAL CONSUMER HEALTH | ||||||||||
| US | 1,787 | 1,687 | 6.0 | 3,522 | 3,244 | 8.6 | ||||
| Intl | 2,224 | 2,118 | 5.0 | 4,341 | 4,147 | 4.7 | ||||
| WW | $ | 4,011 | 3,805 | 5.4 | % | $ | 7,863 | 7,391 | 6.4 | % |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| SECOND QUARTER | SIX MONTHS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % Change | % Change | ||||||||||
| 2023 (Preliminary) | 2022 (Actual) | Reported | 2023 (Preliminary) | 2022 (Actual) | Reported | ||||||
| PHARMACEUTICAL SEGMENT (1) (2) | |||||||||||
| IMMUNOLOGY | |||||||||||
| US | $ | 2,865 | 2,853 | 0.4 | % | $ | 5,313 | 5,354 | (0.8) | % | |
| Intl | 1,631 | 1,559 | 4.7 | 3,295 | 3,176 | 3.8 | |||||
| WW | 4,496 | 4,411 | 1.9 | 8,608 | 8,530 | 0.9 | |||||
| REMICADE | |||||||||||
| US | 277 | 391 | (29.3) | 553 | 749 | (26.2) | |||||
| US Exports (3) | 33 | 44 | (24.9) | 74 | 124 | (40.3) | |||||
| Intl | 152 | 212 | (28.2) | 322 | 437 | (26.2) | |||||
| WW | 462 | 647 | (28.6) | 949 | 1,310 | (27.5) | |||||
| SIMPONI / SIMPONI ARIA | |||||||||||
| US | 285 | 301 | (5.1) | 556 | 588 | (5.4) | |||||
| Intl | 244 | 266 | (8.2) | 510 | 549 | (7.1) | |||||
| WW | 529 | 566 | (6.6) | 1,066 | 1,137 | (6.2) | |||||
| STELARA | |||||||||||
| US | 1,817 | 1,731 | 4.9 | 3,268 | 3,110 | 5.1 | |||||
| Intl | 981 | 868 | 13.0 | 1,974 | 1,777 | 11.1 | |||||
| WW | 2,797 | 2,599 | 7.6 | 5,241 | 4,887 | 7.2 | |||||
| TREMFYA | |||||||||||
| US | 450 | 382 | 17.8 | 856 | 773 | 10.7 | |||||
| Intl | 255 | 214 | 19.4 | 489 | 413 | 18.4 | |||||
| WW | 706 | 597 | 18.3 | 1,346 | 1,187 | 13.4 | |||||
| OTHER IMMUNOLOGY | |||||||||||
| US | 4 | 3 | 17.8 | 7 | 9 | (30.2) | |||||
| Intl | 0 | 0 | — | 0 | 0 | — | |||||
| WW | 4 | 3 | 17.8 | 7 | 9 | (30.2) | |||||
| INFECTIOUS DISEASES | |||||||||||
| US | 395 | 415 | (4.9) | 787 | 876 | (10.2) | |||||
| Intl | 727 | 901 | (19.4) | 1,920 | 1,737 | 10.5 | |||||
| WW | 1,121 | 1,316 | (14.8) | 2,707 | 2,613 | 3.6 | |||||
| COVID-19 VACCINE | |||||||||||
| US | — | 45 | * | — | 120 | * | |||||
| Intl | 285 | 499 | (43.0) | 1,032 | 881 | 17.1 | |||||
| WW | 285 | 544 | (47.7) | 1,032 | 1,001 | 3.0 | |||||
| EDURANT / rilpivirine | |||||||||||
| US | 8 | 9 | (9.0) | 17 | 18 | (5.3) | |||||
| Intl | 258 | 215 | 19.9 | 529 | 454 | 16.4 | |||||
| WW | 266 | 225 | 18.6 | 546 | 473 | 15.6 | |||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||
| US | 382 | 355 | 7.6 | 760 | 724 | 5.0 | |||||
| Intl | 109 | 110 | (0.2) | 208 | 242 | (13.9) | |||||
| WW | 491 | 464 | 5.8 | 968 | 965 | 0.3 | |||||
| OTHER INFECTIOUS DISEASES | |||||||||||
| US | 5 | 6 | (27.2) | 10 | 14 | (30.6) | |||||
| Intl | 74 | 77 | (3.5) | 151 | 160 | (5.6) | |||||
| WW | 79 | 83 | (5.2) | 161 | 174 | (7.6) |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| SIX MONTHS | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| % Change | % Change | ||||||||
| 2022 (Actual) | Reported | 2023 (Preliminary) | 2022 (Actual) | Reported | |||||
| PHARMACEUTICAL SEGMENT (1) (2) (Continued) | |||||||||
| NOSCIENCE | |||||||||
| US | 1,029 | 896 | 14.9 | % | $ | 2,007 | 1,739 | 15.4 | % |
| Intl | 837 | (8.8) | 1,590 | 1,735 | (8.4) | ||||
| WW | 1,734 | 3.5 | 3,597 | 3,475 | 3.5 | ||||
| 38 | 68.2 | 134 | 73 | 84.0 | |||||
| 123 | 16.3 | 279 | 245 | 13.9 | |||||
| 161 | 28.6 | 414 | 318 | 30.0 | |||||
| 691 | 4.3 | 1,434 | 1,352 | 6.0 | |||||
| 362 | (14.4) | 641 | 749 | (14.5) | |||||
| 1,054 | (2.1) | 2,075 | 2,102 | (1.3) | |||||
| 74 | 93.2 | 255 | 135 | 88.3 | |||||
| 11 | * | 45 | 20 | * | |||||
| 85 | 98.2 | 300 | 155 | 93.1 | |||||
| 93 | 9.3 | 184 | 179 | 3.1 | |||||
| 341 | (16.4) | 625 | 721 | (13.4) | |||||
| 433 | (10.9) | 809 | 900 | (10.1) | |||||
| ONCOLOGY | |||||||||
| US | 1,679 | 23.2 | 3,958 | 3,261 | 21.4 | ||||
| Intl | 2,362 | (1.4) | 4,552 | 4,731 | (3.8) | ||||
| WW | 4,042 | 8.8 | 8,510 | 7,992 | 6.5 | ||||
| 24 | * | 184 | 24 | * | |||||
| — | * | 5 | — | * | |||||
| 24 | * | 189 | 24 | * | |||||
| 1,021 | 29.5 | 2,513 | 1,974 | 27.3 | |||||
| 965 | 15.0 | 2,182 | 1,868 | 16.8 | |||||
| 1,986 | 22.4 | 4,695 | 3,842 | 22.2 | |||||
| 233 | 3.6 | 490 | 439 | 11.8 | |||||
| 218 | 49.7 | 619 | 412 | 50.3 | |||||
| 450 | 25.9 | 1,109 | 850 | 30.4 | |||||
| 349 | (24.9) | 532 | 719 | (26.0) | |||||
| 620 | (6.7) | 1,136 | 1,288 | (11.8) | |||||
| 970 | (13.2) | 1,668 | 2,008 | (16.9) | |||||
| 19 | (55.2) | 25 | 38 | (34.7) | |||||
| 486 | (55.1) | 447 | 1,006 | (55.6) | |||||
| 505 | (55.1) | 472 | 1,044 | (54.8) | |||||
| 33 | * | 214 | 67 | * | |||||
| 72 | 27.8 | 162 | 156 | 3.6 | |||||
| 106 | * | 376 | 224 | 68.0 |
All values are in Euros.
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| SECOND QUARTER | SIX MONTHS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % Change | %<br><br>Change | ||||||||||
| 2023 (Preliminary) | 2022 (Actual) | Reported | 2023 (Preliminary) | 2022 (Actual) | Reported | ||||||
| PHARMACEUTICAL SEGMENT (1) (2) (Continued) | |||||||||||
| PULMONARY HYPERTENSION | |||||||||||
| US | $ | 684 | 560 | 22.0 | % | $ | 1,284 | 1,132 | 13.4 | % | |
| Intl | 289 | 284 | 2.0 | 561 | 563 | (0.4) | |||||
| WW | 972 | 843 | 15.3 | 1,844 | 1,695 | 8.8 | |||||
| OPSUMIT | |||||||||||
| US | 328 | 265 | 23.7 | 601 | 538 | 11.6 | |||||
| Intl | 179 | 173 | 3.4 | 346 | 343 | 0.9 | |||||
| WW | 507 | 438 | 15.7 | 947 | 881 | 7.5 | |||||
| UPTRAVI | |||||||||||
| US | 338 | 272 | 24.2 | 642 | 541 | 18.7 | |||||
| Intl | 61 | 56 | 10.0 | 119 | 112 | 6.6 | |||||
| WW | 399 | 328 | 21.8 | 761 | 653 | 16.6 | |||||
| OTHER PULMONARY HYPERTENSION | |||||||||||
| US | 18 | 23 | (23.8) | 41 | 53 | (23.0) | |||||
| Intl | 48 | 55 | (10.9) | 95 | 108 | (11.7) | |||||
| WW | 66 | 78 | (14.7) | 136 | 161 | (15.5) | |||||
| CARDIOVASCULAR / METABOLISM / OTHER | |||||||||||
| US | 776 | 757 | 2.6 | 1,491 | 1,429 | 4.3 | |||||
| Intl | 174 | 215 | (19.0) | 386 | 453 | (14.7) | |||||
| WW | 950 | 972 | (2.2) | 1,877 | 1,882 | (0.3) | |||||
| XARELTO | |||||||||||
| US | 637 | 609 | 4.7 | 1,215 | 1,117 | 8.8 | |||||
| Intl | — | — | — | — | — | — | |||||
| WW | 637 | 609 | 4.7 | 1,215 | 1,117 | 8.8 | |||||
| OTHER | |||||||||||
| US | 138 | 148 | (6.3) | 275 | 312 | (11.8) | |||||
| Intl | 174 | 215 | (19.0) | 386 | 453 | (14.7) | |||||
| WW | 313 | 363 | (13.8) | 662 | 765 | (13.5) | |||||
| TOTAL PHARMACEUTICAL | |||||||||||
| US | 7,818 | 7,159 | 9.2 | 14,841 | 13,791 | 7.6 | |||||
| Intl | 5,913 | 6,158 | (4.0) | 12,303 | 12,395 | (0.7) | |||||
| WW | $ | 13,731 | 13,317 | 3.1 | % | $ | 27,144 | 26,186 | 3.7 | % |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| SECOND QUARTER | SIX MONTHS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % Change | %<br><br>Change | ||||||||||
| 2023 (Preliminary) | 2022 (Actual) | Reported | 2023 (Preliminary) | 2022 (Actual) | Reported | ||||||
| MEDTECH SEGMENT (1) (2) | |||||||||||
| INTERVENTIONAL SOLUTIONS | |||||||||||
| US | $ | 908 | 525 | 73.1 | % | $ | 1,771 | 1,019 | 73.8 | % | |
| Intl | 712 | 525 | 35.7 | 1,352 | 1,123 | 20.5 | |||||
| WW | 1,620 | 1,049 | 54.4 | 3,123 | 2,141 | 45.8 | |||||
| ELECTROPHYSIOLOGY | |||||||||||
| US | 609 | 499 | 22.0 | 1,180 | 969 | 21.7 | |||||
| Intl | 587 | 469 | 25.1 | 1,109 | 1,001 | 10.8 | |||||
| WW | 1,196 | 968 | 23.5 | 2,288 | 1,970 | 16.2 | |||||
| ABIOMED | |||||||||||
| US | 272 | — | * | 536 | — | * | |||||
| Intl | 59 | — | * | 119 | — | * | |||||
| WW | 331 | — | * | 655 | — | * | |||||
| OTHER INTERVENTIONAL SOLUTIONS | |||||||||||
| US | 27 | 26 | 4.5 | 55 | 51 | 10.8 | |||||
| Intl | 67 | 56 | 20.0 | 125 | 121 | 2.8 | |||||
| WW | 93 | 81 | 15.1 | 180 | 171 | 5.1 | |||||
| ORTHOPAEDICS | |||||||||||
| US | 1,388 | 1,338 | 3.7 | 2,751 | 2,627 | 4.7 | |||||
| Intl | 878 | 820 | 7.0 | 1,759 | 1,719 | 2.3 | |||||
| WW | 2,265 | 2,157 | 5.0 | 4,510 | 4,345 | 3.8 | |||||
| HIPS | |||||||||||
| US | 250 | 240 | 4.1 | 491 | 465 | 5.6 | |||||
| Intl | 147 | 148 | (0.8) | 296 | 312 | (5.1) | |||||
| WW | 397 | 388 | 2.2 | 787 | 777 | 1.3 | |||||
| KNEES | |||||||||||
| US | 221 | 216 | 2.4 | 447 | 417 | 7.2 | |||||
| Intl | 142 | 133 | 6.3 | 284 | 271 | 4.8 | |||||
| WW | 363 | 349 | 3.9 | 731 | 688 | 6.3 | |||||
| TRAUMA | |||||||||||
| US | 483 | 464 | 4.3 | 974 | 939 | 3.7 | |||||
| Intl | 255 | 232 | 9.9 | 522 | 505 | 3.2 | |||||
| WW | 739 | 696 | 6.1 | 1,496 | 1,444 | 3.6 | |||||
| SPINE, SPORTS & OTHER | |||||||||||
| US | 433 | 418 | 3.5 | 839 | 805 | 4.1 | |||||
| Intl | 334 | 306 | 9.0 | 657 | 630 | 4.2 | |||||
| WW | 766 | 724 | 5.8 | 1,495 | 1,436 | 4.2 |
See footnotes at end of schedule
Johnson & Johnson
Segment Sales
(Dollars in Millions)
| SECOND QUARTER | SIX MONTHS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % Change | % Change | ||||||||||
| 2023 (Preliminary) | 2022 (Actual) | Reported | 2023 (Preliminary) | 2022 (Actual) | Reported | ||||||
| MEDTECH SEGMENT (1) (2) (Continued) | |||||||||||
| SURGERY | |||||||||||
| US | $ | 1,015 | 992 | 2.2 | % | $ | 1,990 | 1,913 | 4.0 | % | |
| Intl | 1,580 | 1,458 | 8.4 | 3,039 | 2,971 | 2.3 | |||||
| WW | 2,594 | 2,450 | 5.9 | 5,028 | 4,884 | 3.0 | |||||
| ADVANCED | |||||||||||
| US | 466 | 454 | 2.7 | 910 | 871 | 4.5 | |||||
| Intl | 757 | 702 | 7.8 | 1,430 | 1,431 | 0.0 | |||||
| WW | 1,222 | 1,156 | 5.8 | 2,340 | 2,302 | 1.7 | |||||
| GENERAL | |||||||||||
| US | 548 | 538 | 1.9 | 1,079 | 1,042 | 3.6 | |||||
| Intl | 823 | 756 | 8.9 | 1,608 | 1,540 | 4.5 | |||||
| WW | 1,372 | 1,294 | 6.0 | 2,688 | 2,582 | 4.1 | |||||
| VISION | |||||||||||
| US | 529 | 496 | 6.6 | 1,087 | 1,017 | 6.9 | |||||
| Intl | 778 | 745 | 4.6 | 1,521 | 1,481 | 2.7 | |||||
| WW | 1,308 | 1,241 | 5.4 | 2,608 | 2,498 | 4.4 | |||||
| CONTACT LENSES / OTHER | |||||||||||
| US | 409 | 374 | 9.1 | 853 | 774 | 10.1 | |||||
| Intl | 530 | 519 | 2.2 | 1,039 | 1,030 | 0.9 | |||||
| WW | 939 | 894 | 5.1 | 1,892 | 1,804 | 4.9 | |||||
| SURGICAL | |||||||||||
| US | 120 | 122 | (1.1) | 234 | 243 | (3.6) | |||||
| Intl | 249 | 225 | 10.1 | 482 | 451 | 6.7 | |||||
| WW | 369 | 347 | 6.2 | 716 | 694 | 3.1 | |||||
| TOTAL MEDTECH | |||||||||||
| US | 3,839 | 3,351 | 14.6 | 7,598 | 6,576 | 15.5 | |||||
| Intl | 3,949 | 3,547 | 11.3 | 7,671 | 7,293 | 5.2 | |||||
| WW | $ | 7,788 | 6,898 | 12.9 | % | $ | 15,269 | 13,869 | 10.1 | % |
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1)Unaudited
(2)Certain prior year amounts have been reclassified to conform to current year product disclosures
(3)Reported as U.S. sales